Bursa malaysia: Pharmaniaga Bhd will be uplifted from its PN17 status effective 9 am tomorrow. The bourse announced that Pharmaniaga has regularised its financial condition and no longer triggers any criteria under Paragraph 2.1 of PN17 of the Main Market Listing Requirements. Bursa Malaysia affirmed its ongoing commitment to monitor the progress of PN17 and Guidance Note 3 (GN3) companies concerning compliance with Main Market and ACE Market listing requirements.

According to BERNAMA News Agency, Pharmaniaga's managing director, Datuk Zulkifli Jafar, expressed that this achievement is a testament to the resilience, discipline, and collective commitment demonstrated across the organisation during a challenging period. With the PN17 status uplifted, Pharmaniaga aims to focus on strengthening long-term growth and expanding its strategic capabilities across the healthcare value chain. Datuk Zulkifli stated that this transition marks a new phase for Pharmaniaga, shifting from stabilising the business and strengthening its foundation to driving sustainable growth.

Moving forward, Pharmaniaga plans to enhance its pharmaceutical and biopharmaceutical capabilities while deepening its presence in the regional market, working towards building a stronger and more resilient organisation for the future. On February 27, 2023, Pharmaniaga was initially classified as a PN17 company. The group undertook a series of rejuvenation initiatives, with its recovery bolstered by consistent improvements in operational performance. Since the quarter ended March 31, 2024 (1Q FY2024), the company has recorded eight consecutive profitable quarters, resulting in a net profit of RM48.5 million for the financial year ended December 31, 2025 (FY2025).